Table 1 Patient characteristics
Variable | Number of patients (%) |
|---|---|
Age at time of surgery (years) | |
Mean (median) | 62.1 (63) |
<50 | 83 (2.7%) |
50–59 | 834 (27.0%) |
60–69 | 1901 (61.5%) |
>70 | 275 (8.9%) |
Pre-operative PSA (ng/ml) | |
Mean (median) | 9.3 (6.8) |
<3.0 | 266 (8.7%) |
3.0–10.0 | 1922 (63.0%) |
10.1–20.0 | 641 (21.0%) |
>20.0 | 223 (7.3%) |
Clinical stage | |
T1c | 2026 (65.8%) |
T2 | 1009 (32.8%) |
T3 | 44 (1.4%) |
Biopsy Gleason score | |
≤6 | 2045 (68.5%) |
3+4 | 662 (22.2%) |
4+3 | 184 (6.2%) |
≥8 | 90 (3.0%) |
Prostatectomy Gleason score | |
≤6 | 1426 (45.9%) |
3+4 | 1311 (42.2%) |
4+3 | 313 (10.1%) |
≥8 | 54 (1.7%) |
Pathological stage | |
pT2 | 2079 (67.0%) |
pT3 | 980 (31.6%) |
pT4 | 42 (1.4%) |
Extraprostatic extension | 967 (31.3%) |
Positive surgical margins | 627 (20.2%) |
Lymph node involvementa | 95 (5.8%) |
Follow-up (months) | |
Mean (median) | 44.5 (34.3) |
Range | 0.0–192.6 |
Overall no. of biochemical recurrences | 620 (20%) |
